The Medspa Market Isn’t Slowing—It’s Sorting Winners

For much of the last decade, the medical aesthetics industry operated like a frontier town — wide open, fast-growing, and highly forgiving. Demand followed supply, and competent operators could build meaningful businesses quickly. That phase is now evolving.

Walking the halls at the AmSpa Medical Spa Show 2026 in Las Vegas, the defining theme was discernment rather than exuberance. Interest remains strong, but expectations have risen. The industry is entering a more disciplined phase of growth.

The backdrop remains compelling. The medspa market has scaled into a $20B+ global category and continues to expand at an attractive rate based on recent industry estimates. Capital remains active, now with greater selectively.

The Flight to Quality

Buyers today bring a higher level of underwriting discipline, focusing on what drives durability: provider stability, patient retention, service mix, and compliance infrastructure.  Scale alone no longer carries the narrative. Today, quality is underwritten.

This is most visible in add-on acquisitions. While average multiples may appear modestly lower, this reflects a broader mix of assets rather than reduced demand. The market now includes a wider range of practices, not all of which meet institutional standards. High quality platforms remain scarce and continue to command premium valuations, with leading assets achieving double-digit multiples of EBITDA.

For investors, that is an advantage rather than a headwind. Greater dispersion is creating clearer opportunities to back differentiated, durable platforms.

Patient Demand Is Evolving

Consumer demand remains healthy, but growth is becoming more nuanced. Core injectable categories continue to perform well. At the same time, the mix is shifting.

Legacy products like Botox remain foundational but face rising competition from alternatives such as Dysport, Xeomin, Jeuveau, and Daxxify. Concurrently, demand is migrating toward biostimulatory injectables such as Sculptra and toward energy-based treatments, including lasers, radiofrequency, and ultrasound.

The key question is not whether consumers are spending – it is whether providers are positioned to capture where that spending is going. The leading practices are those that anticipated this shift and evolved their service offerings accordingly.

Importantly, this dynamic is also improving provider economics. Increased competition among manufacturers, particularly in neuromodulators, is driving greater rebates, incentives, and pricing flexibility. In a category historically concentrated among a few players, this represents a meaningful tailwind for operators.

The Business Is the Provider

In medical aesthetics, the core asset is the provider, who leaves the building every night. Recruiting, training, and retaining clinicians has become the defining operational priority and the primary source of competitive advantage.

Leading platforms are investing accordingly. Structured training, mentorship, and clear advancement pathways are becoming standard. Culture and professional development are no longer soft considerations – they are central to performance.

These investments translate directly into higher provider productivity, stronger patient relationships, and more durable financial performance. At the same time, top operators pair clinical excellence with effective demand generation. Digital marketing, membership models, and brand positioning are leveraged to consistently drive utilization and optimize treatment mix.

The platforms that combine these capabilities are the ones compounding. 

The Next Layer: Longevity

An emerging area of focus is the integration of longevity and wellness services. Hormone optimization, medical weight loss, peptides, IV therapy, and broader wellness offerings are moving from adjacent services to integrated components of the platform.

The opportunity is significant, but execution remains uneven. The most successful operators are approaching this expansion with discipline, building the clinical infrastructure, compliance frameworks, and physician oversight required to integrate these services effectively.

When executed well, these services enhance patient retention and lifetime value, shifting the model from transactional to ongoing engagement.

The Takeaway

The medspa industry is entering its next phase of growth, which will be defined by discipline, differentiation, and operational excellence. Quality, talent, and adaptability now drive outcomes. Capital remains active. Demand remains strong. What has changed is how selectively both are deployed.

For investors, the shift is constructive. The gap between good and great operators is widening. In markets like this, value doesn’t disappear. It concentrates.

Mark Carl is a Managing Director in the Healthcare group at Livingstone, a global mid-market investment bank providing M&A and debt advisory services. Livingstone is among the most active advisors in middle-market healthcare, with deep experience advising founder-led and scaled, consumer-facing platforms and particular expertise in medical aesthetics and longevity.